Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. (VSTM) on October 24, 2023. The filing discloses the appointment of a new Chief Financial Officer and the terms of the associated employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
- Base Salary: $300,000 annually.
- Annual Bonus Target: 35% of base salary.
- Stock Option Grant: 25,000 shares at an exercise price of $6.89 per share.
Material Changes
On October 24, 2023, the Board of Directors appointed Daniel Calkins as Chief Financial Officer. Mr. Calkins had previously served as the principal financial officer and principal accounting officer on an interim basis since October 31, 2022. This appointment formalizes his role and supersedes any prior employment agreements.
Outlook, Risks, and Unusual Items
The filing details severance provisions triggered by termination without Cause or for Good Reason:
- Standard Termination: Nine months of base salary continuation and COBRA premium coverage for nine months.
- Change of Control Termination: If termination occurs within 90 days prior to or 18 months following a Change of Control, benefits increase to 12 months of base salary, 12 months of COBRA coverage, a pro-rata target bonus, and accelerated vesting of time-based equity awards.
Performance-based equity awards vest upon a Change of Control to the extent they are not assumed by the acquirer.
Investor Verification Checklist
- Verify the vesting schedule for the 25,000 stock options granted (25% at one-year anniversary, then 6.25% quarterly).
- Review the full Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the pro-rated bonus calculation for the period prior to October 19, 2023, as it follows prior terms.